The beneficial impact of EGFR TKIs has been mainly investigated by the combination of erlotinib and gefitinib with radiotherapy or chemoradiotherapy in non-small cell lung cancer (NSCLC) as well as HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.